• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by GeoVax Labs Inc.

    6/6/25 4:02:31 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOVX alert in real time by email
    S-8 1 govx20250602_s8.htm FORM S-8 govx20250602_s8.htm

     

    As filed with the Securities and Exchange Commission on June 6, 2025

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    GEOVAX LABS, INC.

    (Exact name of registrant as specified in its charter)

     

     


    Delaware

    (State or other jurisdiction of

    incorporation or organization)

    87-0455038

    (I.R.S. Employer

    Identification No.)

    1900 Lake Park Drive, Suite 380

    Smyrna, Georgia

    (Address of Principal Executive Offices)

    30080

    (Zip Code)

     

    GeoVax Labs, Inc. 2025 Stock Incentive Plan

    (Full title of the plan)

     

    Mark Reynolds

    GeoVax Labs, Inc.

    1900 Lake Park Drive, Suite 380

    Smyrna, Georgia 30080

    (678) 384 -7220

    (Name, address and telephone number, of agent for service)

     


     

    Copy to:

    F. Reid Avett, Esq.

     

    Womble Bond Dickinson (US) LLP

    2001 K Street, NW, Suite 400 South

    Washington, DC 20006

    (202) 857-4425

     


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act, as amended.

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☑

    Smaller reporting company ☑

      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by GeoVax Labs, Inc., a Delaware corporation (the “Registrant”), with respect to 1,700,000 shares of common stock, par value $0.001 per share (“Common Stock”) of the Registrant, which may be issued under the GeoVax Labs, Inc. 2025 Stock Incentive Plan (the “Plan”).

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 424 under the Securities Act of 1933, as amended (the “Securities Act”). The documents containing the information specified in Part I will be delivered to plan participants as required by Rule 428(b)(1).

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have previously been filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”), are incorporated by reference herein and shall be deemed to be a part hereof:

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on March 27, 2025, including information specifically incorporated by reference into the Form 10-K from the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 14, 2025;

     

    (b)

    The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, filed on May 1, 2025;

     

    (c)

    The Registrant’s Current Reports on Form 8-K, filed on January 22, 2025; March 25, 2025; April 14, 2025 and June 5, 2025; and

     

    (d)

    The description of the Common Stock contained in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on March 27, 2025, including any amendment or report filed for the purpose of updating such description.

     

    All reports and/or documents filed by the Registrant with the SEC under Sections 13(a), 13(c), 14 or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), except for such reports and/or documents (or portions thereof) that are “furnished” to the SEC or that are otherwise not deemed to be filed with the SEC pursuant to such Exchange Act sections, subsequent to the date hereof and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of such filing.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

     

     

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    The Registrant’s bylaws provide that the Registrant may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Registrant) by reason of the fact that the person is or was a director, officer, employee or agent of the Registrant, or is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Registrant, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. The Registrant’s bylaws also provide that the Registrant may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Registrant to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the Registrant, or is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Registrant and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Registrant unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper.

     

    Under the Registrant’s bylaws, expenses (including attorneys’ fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Registrant in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Registrant. Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any, as the Registrant deems appropriate.

     

    The indemnification and advancement of expenses provided by the Registrant’s bylaws is not exclusive, both as to action in such person’s official capacity and as to action in another capacity while holding such office.

     

     

     

     

    The Registrant’s bylaws also provide that the Registrant may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Registrant, or is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the Registrant would have the power to indemnify such person against such liability under the Registrant’s bylaws. The Registrant maintains an insurance policy providing for indemnification of its officers, directors and certain other persons against liabilities and expenses incurred by any of them in certain stated proceedings and under certain stated conditions.

     

    In October 2006, the Registrant and its subsidiary, GeoVax, Inc., entered into indemnification agreements with Messrs. McNally, Reynolds, Kollintzas and Spencer. Pursuant to these agreements, the Registrant has agreed to hold harmless and indemnify these directors and officers to the full extent authorized or permitted by applicable Illinois and Georgia law against certain expenses and other liabilities actually and reasonably incurred by these individuals in connection with certain proceedings if they acted in a manner they believed in good faith to be in or not opposed to the best interests of the Registrant and, with respect to any criminal proceeding, had no reasonable cause to believe that such conduct was unlawful. The agreements also provide for the advancement of expenses to these individuals subject to specified conditions. Under these agreements, the Registrant will not indemnify these individuals for expenses or other amounts for which applicable Illinois and Georgia law prohibit indemnification. The obligations under these agreements continue during the period in which these individuals are the Registrant’s directors or officers and continue thereafter so long as these individuals shall be subject to any proceeding by reason of their service to the Registrant, whether or not they are serving in any such capacity at the time the liability or expense incurred for which indemnification can be provided under the agreements.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    In the event that a claims for indemnification against such liabilities (other than the Registrant’s payment of expenses incurred or paid by a director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of the Registrant’s counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by the Registrant is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit No.

    Description

    4.1

    Restated Certificate of Incorporation filed April 12, 2024 (1)

    4.2

    Bylaws (2)

    5.1

    Opinion of Womble Bond Dickinson (US) LLP regarding the legality of the securities being registered *

    23.1

    Consent of Wipfli LLP (U.S. PCAOB Auditor Firm ID 344) *

    23.2

    Consent of Womble Bond Dickinson (US) LLP (included in Exhibit 5.1) *

    24

    Powers of Attorney (included on signature page) *

    99.1

    GeoVax Labs, Inc. 2025 Stock Incentive Plan *

    107.1

    Filing Fee Table *

     

    *Filed herewith

     

    (1)

    Incorporated by reference from the registrant’s Quarterly Report on Form 10-Q filed May 14, 2024.

    (2)

    Incorporated by reference from the registrant’s Current Report on Form 8-K filed May 23, 2024.

     

     

     

     

    Item 9. Undertakings.

     

     

    (a)

    The undersigned Registrant hereby undertakes:

     

     

    (1)

    to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)

    to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)

    to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; and

     

    (iii)

    to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with, or furnished to, the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with, or furnished to, the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement;

     

     

    (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

     

     

    (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

     

    (b)

    The undersigned Registrant hereby undertakes that, for the purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

     

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Smyrna, State of Georgia, on June 6, 2025.

     

    GEOVAX LABS, INC.

     

     

    By:

    /s/ David A. Dodd

       

    Name:

    David A. Dodd

       

    Title:

    President and Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of the Registrant, hereby severally constitute and appoint [David A. Dodd and Mark W. Reynolds], and each of them, our true and lawful attorneys-in-fact and agents with full power to sign for us, and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all pre-effective and post-effective amendments to said registration statement, to file the same, and generally to do all such things in our name and on our behalf in our capacities as officers and directors of the Registrant, in connection with the transaction contemplated by said registration statement, to enable the Registrant to comply with the provisions of the Securities Act, as amended, and all requirements of the SEC, hereby ratifying and confirming our signatures as they may be signed by our said attorneys-in-fact to said registration statement and any and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated as of June 6, 2025.

     

    Signature

     

    Position

         

    /s/ David A. Dodd

     

    Chairman, President and Chief Executive Officer

    David A. Dodd

     

    (Principal Executive Officer)

         

    /s/ Mark W. Reynolds

     

    Chief Financial Officer

    Mark W. Reynolds

     

    (Principal Financial Officer)

         

    /s/ Randal D. Chase

     

    Director

    Randal D. Chase, PhD

       
         

    /s/ Dean G. Kollintzas

     

    Director

    Dean G. Kollintzas

       
         

    /s/ Nicole Lemerond

     

    Director

    Nicole Lemerond

       
         

    /s/ Robert T. McNally

     

    Director

    Robert T. McNally, PhD

       
         

    /s/ Jayne Morgan

     

    Director

    Jayne Morgan, MD

       
         

    /s/ John N. Spencer, Jr.

     

    Director

    John N. Spencer, Jr.

       

     

     
    Get the next $GOVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GOVX

    DatePrice TargetRatingAnalyst
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    11/11/2024$15.00Buy
    Alliance Global Partners
    7/16/2024$20.00Buy
    ROTH MKM
    More analyst ratings

    $GOVX
    SEC Filings

    See more
    • SEC Form S-8 filed by GeoVax Labs Inc.

      S-8 - GeoVax Labs, Inc. (0000832489) (Filer)

      6/6/25 4:02:31 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - GeoVax Labs, Inc. (0000832489) (Filer)

      6/5/25 4:40:26 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:08:24 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Lemerond Nicole

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      6/6/25 9:51:40 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chase Randal D

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      6/6/25 9:50:36 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kollintzas Dean G

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      6/6/25 9:49:19 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/11/25 1:23:33 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/10/25 4:01:15 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/1/25 4:46:16 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Financials

    Live finance-specific insights

    See more
    • GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

      Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end

      11/12/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

      GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available

      11/5/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

      Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin

      8/6/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

      MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t

      4/16/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

      MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register

      4/15/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

      MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

      3/26/25 7:00:00 AM ET
      $AEMD
      $ASPI
      $ATCH
      $BNRG
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      11/14/24 5:10:48 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GeoVax Labs Inc.

      SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)

      2/14/24 3:38:25 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      2/10/21 3:16:30 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital reiterated coverage on GeoVax Labs with a new price target

      D. Boral Capital reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $14.00 from $18.00 previously

      4/15/25 7:54:48 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners reiterated coverage on GeoVax Labs with a new price target

      Alliance Global Partners reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $8.50 from $15.00 previously

      4/15/25 7:54:17 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners initiated coverage on GeoVax Labs with a new price target

      Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00

      11/11/24 7:40:44 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Leadership Updates

    Live Leadership Updates

    See more
    • GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

      Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci

      8/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

      Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology.  Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development

      1/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

      First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear

      12/20/22 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care